PSEN1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL33171	1.00	20/20
SCHEMBL137789	1.00	20/20
SCHEMBL139302	1.00	20/20
SCHEMBL136503	0.76	20/20
SCHEMBL154957	0.66	20/20
SCHEMBL138898	0.66	20/20
SCHEMBL139605	0.66	20/20
Hydrochloric Acid (SCHEMBL154119)	0.65	20/20
SCHEMBL139065	0.64	20/20
SCHEMBL151407	0.62	20/20
SCHEMBL138968	0.61	20/20
SCHEMBL139498	0.60	20/20
SCHEMBL154717	0.58	20/20
SCHEMBL139470	0.58	20/20
SCHEMBL139515	0.58	20/20
SCHEMBL139460	0.58	20/20
SCHEMBL155625	0.57	20/20
SCHEMBL138951	0.56	20/20
SCHEMBL156201	0.56	20/20
SCHEMBL138067	0.55	20/20

Clinical trials — most relevant to PSEN1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Lithium As a Treatment to Prevent Impairment of Cognition in Elders	PHASE4	COMPLETED
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)	PHASE4	COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.	PHASE2/PHASE3	COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	PHASE2/PHASE3	RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	PHASE2/PHASE3	RECRUITING
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort	PHASE2	COMPLETED
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)	PHASE2	COMPLETED
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants	PHASE1	ACTIVE_NOT_RECRUITING
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease	PHASE1	COMPLETED
Exploratory and Safety Study of [F-18]W372	EARLY_PHASE1	COMPLETED
Apolipoprotein E Gene and Functional MRI	nan	COMPLETED
The Evaluation and Follow-up of Individuals With Memory Disorder	nan	COMPLETED
Prognostic Observation of Posterior Reversible Encephalopathy Syndrome	nan	UNKNOWN
Central and Systemic Inflammation in Alzheimer's Disease	nan	COMPLETED
Late Onset Alzheimer's Disease	nan	RECRUITING
The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition	nan	COMPLETED
The Genetic Characterization of Dementia	nan	COMPLETED
The Signature of Alzheimer's Disease in Subjective Cognitive Decline	nan	RECRUITING
Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease	nan	COMPLETED
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)	nan	COMPLETED
Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients	nan	COMPLETED
tACS for Amyloid-β Reduction in Alzheimer's Disease	nan	COMPLETED
Dominantly Inherited Alzheimer Network (DIAN)	nan	RECRUITING
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)	nan	COMPLETED
Predicting Pre-dementia	nan	RECRUITING
Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients	nan	WITHDRAWN
The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4	nan	RECRUITING
Attenuation of Postprandial Inflammatory Processes in Alzheimer's Disease Patients by Consumption of Pomace Oil	nan	ACTIVE_NOT_RECRUITING
IGF and Other Neurotrophic Factors in Patients With Dementia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PSEN1 binder may also engage these)

Protein	Name	Similarity
Q6RH31	—	1.000	Q6RH31 →
Q5R780	—	1.000	Q5R780 →
P49769	—	1.000	P49769 →
Q90ZE4	—	1.000	Q90ZE4 →
Q8HXW5	—	1.000	Q8HXW5 →
O12976	—	1.000	O12976 →
P79802	—	1.000	P79802 →
Q90X07	—	1.000	Q90X07 →
O12977	—	0.998	O12977 →
Q0MS45	—	0.998	Q0MS45 →
O88777	—	0.998	O88777 →
PSEN2	Presenilin-2	0.997	landscape →
Q4JIM4	—	0.997	Q4JIM4 →
Q9W6T7	—	0.997	Q9W6T7 →
P52166	—	0.996	P52166 →
Q61144	—	0.996	Q61144 →
Q9XT97	—	0.996	Q9XT97 →
P97887	—	0.995	P97887 →
O64668	—	0.995	O64668 →
Q5RCN9	—	0.992	Q5RCN9 →
Q9XT96	—	0.992	Q9XT96 →
Q9SIK7	—	0.991	Q9SIK7 →
P79801	—	0.991	P79801 →
O02194	—	0.990	O02194 →
O02100	—	0.986	O02100 →
Q6NZ21	—	0.986	Q6NZ21 →
F1RAX4	—	0.985	F1RAX4 →
A0A061ACU2	—	0.985	A0A061ACU2 →
Q3T0S0	—	0.985	Q3T0S0 →
A8WWR3	—	0.984	A8WWR3 →